Overview

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).

Phase:

Early Phase 1

Details

Lead Sponsor:

University of California, Davis

Treatments:

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid